San Francisco startup Structure Therapeutics can also be focusing on an oral, once-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June every time a mid-stage review confirmed normal weight loss of around 6% and it options to start out One more mid-stage demo to the top of this year—that founder and CEO